Monday, September 26, 2016

MicuRx Pharmaceuticals Gets $55M For Antibiotics Development

Hayward-based MicuRx Pharmaceuticals, which is developing oral and intravenous antibiotics to treat MRSA, has raised $55M in a Series C funding, the company announced this morning. The funding was led by GP Healthcare Capital, and also included GP TMT Capital, 3E Bioventures Capital, and Delian Capital. Yu Miao of GP Healthcare Capital joins the company's board with the funding. MicuRx is led by Zhengyu Yuan, Ph.D. MicuRx has now raised around $90M in total funding. More information »